​What are you looking for?

⭐  BioNTech SE  and  Bristol Myers Squibb  entered into a global strategic partnership with a 50/50 profit/loss split to co-develop and co-commercialize BNT327 (PD-L1xVEGF-A BsAb) across numerous solid tumor types (Ref 1). ⭐ BMS will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. ⭐ In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. ⭐ BioNTech obtained BNT327 through the acquisition of Biotheus in a ~$950 million deal (Ref 2). 📝 To know further details about current development status of BNT327, and competitive landscape of BsAbs, please write to us at  support@oncofocus.com . 🌐 References: 1) https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx 2) https://investors.biontech.de/news-releases/news-release-details/biontech-completes-acquisition-biotheus

“The right target, at the right time, for the right price”  …is and always has been a guiding principle for Merck KGaA, as stated by its CEO, Belen Garijo. It appears that Merck KGaA has now identified the ‘right’ acquisition target - SpringWorks Therapeutics. As reported by Reuters, Merck KGaA is in advanced talks to acquire the US-based cancer and rare disease biotech SpringWorks. The potential deal, which could be finalized in the coming weeks, is expected to expand Merck’s oncology pipeline, amid its recent clinical setbacks, including the failure of xevinapant. SpringWorks’ Key Assets: 👉 Ogsiveo (nirogacestat; gamma secretase inhibitor) - Approved as a monotherapy in the US for adult desmoid tumors. It generated $61.5M in net revenue in Q4’24, with full-year 2024 sales reaching $172M. - Ongoing clinical trials aim to expand its indication to pediatric desmoid tumors, ovarian granulosa cell tumors, and multiple myeloma. 👉 Mirdametinib (MEK Inhibitor) – Currently under priority review by the US FDA for adult and pediatric NF1-associated plexiform neurofibromas, with the regulatory decision expected by Feb’25. The drug has received Orphan Drug, Fast Track and Rare Pediatric Disease designations for this indication. - Additionally, it is under development for other cancers, including pediatric low-grade gliomas, RAS/RAF mutant and other MAPK pathway aberrant solid tumors 👉 Other early-stage assets include brimarafenib (BGB-3245; RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), SW-3431 (PP2A Activator) Some of the interesting questions related to this potential acquisition are -   What are the strategic synergies between these two organizations? Which potential combinations could enter clinical trials post-acquisition? What is the long-term revenue potential of Ogsiveo (nirogacestat) and mirdametinib? Please engage us for a detailed analysis –  support@oncofocus.com

15/05/2025 Another TIGIT agent fails as iTeos and GSK terminate the belrestotug development program based on disappointing NSCLC and SCCHN trials ( Ref 1 , Ref 2 ) iTeos Therapeutics and GSK announced topline results from an updated interim analysis of the Ph2 GALAXIES Lung-201 trial of iTeos & GSK's belrestotug (anti-TIGIT) + GSK & Anaptys' dostarlimab (anti-PD-1) as a first-line Tx of unresectable, locally advanced or metastatic NSCLC with PD-L1 ≥50%, in which clinically meaningful improvements in ORR (primary endpoint) were observed.  However, clinically meaningful improvements in PFS (secondary endpoint) were not achieved with belrestotug + dostarlimab cohorts vs dostarlimab mono Also, in the Ph2 GALAXIES H&N-202 trial, belrestotug combination cohorts showed a trend below the meaningful threshold for ORR vs dostarlimab mono as a first-line Tx of R/M SCCHN with PD-L1 CPS ≥1. Based on these results, iTeos and GSK announced the decision to terminate the belrestotug development program and end the collaboration: All belrestotug-containing cohorts will end, and any new enrollment in the ongoing Ph3 GALAXIES Lung-301 trial in NSCLC is also ending The companies are discussing with investigators, institutional review boards, ethics committees, and health authorities about next steps for appropriate management of currently enrolled pts Eftilagimod alpha + pembrolizumab + chemo continued to show promising ORR in non-sq NSCLC pts regardless of PD-L1 status ( Ref 3 , Ref 4 ) Immutep announced updated response outcomes from the Ph1 INSIGHT-003 trial of Immutep & EOC Pharma's eftilagimod alpha (soluble LAG-3 protein) + pembrolizumab + chemotherapy as a first-line Tx of metastatic, non-squamous NSCLC . At a data cutoff of May 06, 2025 (N=51), an ORR of 60.8% and DCR of 90.2% were demonstrated ORR (PD-L1 <1%, n=22): 54.5% ORR (PD-L1 1-49%, n=25): 64.0% ORR (PD-L1 ≥50%, n=4): 75.0% A favorable safety profile for the triple combination was observed with no new safety signals Additional data updates from this trial are expected to be presented at a medical conference in 2025 and beyond Per previously reported results (Ref 4), the combo elicited the following survival outcomes (data cutoff of Oct 15, 2024; minimum follow-up of 22.0 mos; PD-L1 unselected pts with mature survival data, n=21): mPFS: 12.7 mos mOS: 32.9 mos

29/04/2025 ALX Oncology’s Phase 2 ASPEN-03 & ASPEN-04 trials failed to meet the primary endpoint of ORR ( Ref 1 ) ALX Oncology hit with a double blow in first-line R/M SCCHN as their Phase 2 ASPEN-03 & ASPEN-04 trials evaluating evorpacept, a CD47-blocker, in combination with pembrolizumab with or without chemotherapy did not meet the primary endpoints of improved ORR. While data showed trends in improvement versus historical controls, the signals were not strong enough to advance the regimen into a registrational study The safety profile for the combination was consistent with historical data of pembrolizumab and chemotherapy in this setting These Phase 2 trials were initiated based on promising outcomes reported in the Phase 1 ASPEN-01 trial evaluating evorpacept + pembrolizumab + chemotherapy   The triplet had elicited an ORR of 38.5% and mPFS of 5.6 mos, while mOS was not reached in a small pool of 13 patients These results had also led to the US FDA granting the fast track designation to the regimen   The Phase 3 KEYNOTE-689 trial of neoadjuvant pembro followed by adjuvant pembro + SOC met the primary endpoint of EFS ( Ref 2 , Ref 3 ) : Merck & Co./MSD reported results from the Phase 3 KEYNOTE-689 trial of pembrolizumab (anti-PD-1) as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced HNSCC during a Plenary Session at the AACR Annual Meeting 2025. Neoadjuvant pembrolizumab followed by adjuvant pembrolizumab + SOC significantly improved EFS vs SOC alone mEFS: 51.8 vs 30.4 mos (HR: 0.73; p=0.0041) MPR: 9.4% vs 0.0% At the first interim analysis, the OS did not reach the statistical significance in PD-L1 CPS ≥ 10 patients; additional follow-up is ongoing mOS: NR vs 61.8 mos; HR: 0.72; p=0.02 Due to the statistical testing hierarchy, formal testing was not performed in the CPS ≥1 and ITT populations. OS will be evaluated at the next interim analysis A supplemental Biologics License Application for the regimen is under priority review with the FDA, and a PDUFA date of June 23, 2025 has been set

24/04/2025 Ivonescimab Plus Chemotherapy Shows Statistically Significant Superiority Over Tislelizumab in First-Line Treatment of Squamous NSCLC ( Ref 1 ) Akeso and Summit Therapeutics ' ivonescimab, a PD-1/VEGF bispecific antibody (BsAb), in combination with chemotherapy, met its primary endpoint of progression-free survival (PFS) in the Phase 3 HARMONi-6 trial versus tislelizumab (anti-PD-1) + chemotherapy as a first-line treatment of advanced, squamous non-small cell lung cancer (sq-NSCLC). Detailed results from the HARMONi-6 study will be presented at an upcoming medical conference later this year, potentially at ASCO 2025 Annual Meeting The BsAb regimen not only achieved a statistically significant improvement in the intention-to-treat population, but also demonstrated clinically meaningful PFS benefits in both PD-L1-positive and PD-L1-negative subgroups Ivonescimab demonstrated a favorable safety profile, with no new safety signals identified To note, the HARMONi-6 study has been sponsored by Akeso and enrolled patients at sites only in China Previously, ivonescimab also tasted success in first-line NSCLC with the Phase 3 HARMONi-2 trial, in which ivonescimab significantly improved PFS versus pembrolizumab in advanced, PD-L1 positive NSCLC patients Nivolumab Plus Ipilimumab for Untreated Unresectable or Metastatic Colorectal Cancer with High MSI or dMMR ( Ref 2 ) The UK's NICE has recommended the use of Bristol Myers Squibb ’s Opdivo (nivolumab; anti-PD-1) and Yervoy (ipilimumab; anti-CTLA-4) within its marketing authorisation, as a treatment option for adult, untreated, unresectable or metastatic colorectal cancer (CRC) patients with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). Clinical data of nivolumab + ipilimumab versus chemotherapy from the Phase 3 CheckMate-8HW trial, and indirect comparison versus pembrolizumab suggested that the combination showed improved outcomes in these patients Additionally, the cost-effectiveness estimates of the combination were within the range that NICE considers an acceptable use of NHS resources, allowing for the recommendation To note, the combination can be used only if BMS provides it according to the commercial arrangements as mentioned below: A simple discount patient access scheme for nivolumab and a patient access scheme plus commercial access agreement for ipilimumab allow these products to be available to the NHS with a discount

Dear Readers, Welcome to our inaugural CGT Watch newsletter! We’re excited to bring you monthly highlights on novel targets, innovative therapeutic approaches, and emerging companies in the cell and gene therapy space. Since we’re keen to keep things concise and focused, this issue will exclusively cover cell therapies. We’re using a 45-day window for these highlights; from our next issue onward, we’ll transition to a monthly update schedule. Section 1: Key Monthly Updates 🎯 Regulatory Events ⭐   Bristol Myers Squibb ’s Breyanzi EU Approval for Follicular Lymphoma (FL) ( Ref ) The European commission granted approval to BMS’ Breyanzi (lisocabtagene maraleucel; an autologous, anti-CD19 CAR-T) for the treatment of adult patients with ≥3L FL. 👉  Why it matters:  Breyanzi demonstrated higher ORR (97.1%) compared to the other two CAR-Ts that are approved for the treatment of FL in Europe. This positions Breyanzi as a leading CAR-T option for the patients with R/R FL. ⭐ FTD Designation for Azer-cel ( Ref ) The US FDA granted Fast Track Designation (FTD) to  Imugene Limited ’s azercabtagene zapreleucel (azer-cel; an allogeneic, anti-CD19 CAR-T) for the treatment of R/R DLBCL patients who progressed on prior therapies, including autologous CAR-T. 👉  Why it matters:  Azer-cel is the only active allogeneic CAR-T with FTD for DLBLC patients who progressed on prior treatments, including autologous CAR-T. If azer-cel can reproduce the strong efficacy data in a large trial, it can become the first approved allogeneic CAR-T for these patients. ⭐  NMPA Grants BTD to CARsgen’s Satri-Cel ( Ref ) China’s NMPA granted Breakthrough Therapy Designation (BTD) to  CARsgen Therapeutics ’s satricabtagene autoleucel (satri-cel; CT041; an autologous, anti-CLDN18.2 CAR-T) for the treatment of Claudin18.2-positive ≥3L G/GEJ cancer. 👉  Why it matters:  Satri-cel achieved a statistically significant improvement in the primary endpoint of PFS in the Phase 2/NCT04581473 trial for this patient population. With this designation, satri-cel takes a significant step forward, and the company aims to submit an NDA to the NMPA in the H1’25. 🤝 Mergers & Acquisitions ⭐  BMS to Acquire 2Seventy Bio ( Ref ) Bristol Myers Squibb  is set to acquire  2seventy bio  in an all-cash transaction valued at approximately $286 million. This acquisition gives BMS full control of Abecma (idecabtagene vicleucel)—an autologous, anti-BCMA CAR‑T therapy indicated for the treatment of adult patients with relapsed/refractory multiple myeloma (MM) who have undergone at least two prior lines of therapy. 👉  Why it matters:  After factoring in 2Seventy Bio’s cash reserves, the net acquisition cost for BMS is around $102 million, making it a highly cost-effective investment. This deal allows BMS to fully leverage Abecma's potential without any profit-sharing obligations, potentially yielding returns within two years. ⭐  AstraZeneca's $1B Move in In Vivo Cell Therapy ( Ref ) AstraZeneca  concluded a $1 billion agreement to acquire  EsoBiotec , a company specializing in in vivo cell therapies. AstraZeneca will be paying $425 million upfront with an additional $575 million in milestone-based payments. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform employs highly targeted lentiviruses to deliver genetic instructions directly to specific immune cells—such as T cells—programming them to recognize and destroy tumor cells. 👉  Why it matters:  This acquisition will enhance AstraZeneca's cell therapy capabilities by leveraging the ENaBL platform to modify immune cells directly within the body, thereby reducing complexity and eliminating treatment delays. 🔬 Clinical Events ⭐  NexCAR19 Achieves 72.5% ORR ( Ref ) The Phase 1/2 results of  ImmunoACT ’s NexCAR19 (talicabtagene autoleucel; an autologous, anti-CD19 CAR-T) were published, showcasing an ORR of 72.5% (37 out of 51 efficacy-evaluable patients; 36 with B-cell Lymphoma and 15 with B-ALL). These results led to the approval of NexCAR19 in India in Oct 2023. 👉  Why it matters:  NexCAR19 is India's first homegrown approved CAR-T therapy, developed by ImmunoACT in collaboration with  IIT Bombay  and  Tata Memorial Centre . With its impressive ORR and lower cost, NexCAR19 represents an effective and accessible treatment option for patients. ⭐  First Fast-Manufactured CEA CAR-T ( Ref ) Long manufacturing time has been a bottleneck in providing quick access to approved CAR-Ts to eligible patients. The biopharma companies have been exploring various strategies to manufacture CAR-Ts rapidly. Chongqing Precision Biotech initiated a Phase 1 trial for the first fast-manufactured CAR-T targeting carcinoembryonic antigen (CEA) in CEA-positive advanced malignant solid tumors. 👉  Why it matters:  Because CEA-positive cancers are especially aggressive, faster manufacturing can significantly improve timely and effective treatment. ⭐  AND-gated RevCAR-T Platform: Next-Level Precision  ( Ref ) The   Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , in collaboration with the German Cancer Consortium (DKTK) and the  DKFZ German Cancer Research Center  , continues to advance its dual RevCAR-T platform. The dual RevCAR-T platform uniquely allows precise control over CAR-T cell activation through reversible targeting modules. Recently, they introduced a novel AND-gated antigen combination of PD-L1 & PSCA for their dual RevCAR-T which demonstrated significant tumor size reduction in Prostate Cancer preclinical models. 👉  Why it matters:  This AND-gated RevCAR-T system aims to increase specificity and reduce off-target effects—a major step in making CAR-T therapies safer. ⭐  Tackling Off-Target Toxicity in AML  ( Ref ) In Acute Myeloid Leukemia (AML), off-target toxicity affecting hematopoietic stem cells remains a critical challenge. To mitigate this, the   University of Pennsylvania  has refined its bispecific split CAR-T (bissCAR) cells—comprising a nanobody targeting CD13 and an scFv targeting TIM-3 by developing novel cognate nanobody-directed bispecific anti-CD13/TIM3 nbiCARTs, demonstrating significant promise in preclinical AML models. 👉  Why it matters:  Off-target toxicity is often a deal-breaker in AML CAR-T therapies. Positive early findings could pave the way for safer treatments. ⭐  EU’s Clinical Trial Authorisation for Non-viral Edited TCR-T ( Ref ) Anocca received Clinical Trial Application (CTA) authorisation from the regulatory authorities in four European countries under the EU harmonised framework, for Phase 1/2/VIDAR-1 clinical trial evaluating ANOC-001 (KRAS G12V targeting non-viral gene edited TCR-T) for the treatment of PDAC. 👉  Why it matters:  This CTA approval represents the first regulatory authorisation in Europe to study a non-viral gene-edited TCR-T therapy in clinical practice, representing a significant milestone in advancing innovative cell therapy technologies. ⭐  What’s New in the CAR-NK Space?  ( Ref 1 ;  Ref 2 ) Shanghai Vitalgen Bio initiated a Phase 0 trial for its VGO-Cs01p, a CAR-NK therapy targeting CD7 in relapsed/refractory (R/R) T-cell Acute Lymphoblastic Leukemia. Xinxiang Medical University is exploring CAR-NK92 therapy with a dual-targeted approach (PD-L1 and MICA/B) for lung cancer, a heterogenous cancer that demands multitargeted approach. Preclinical studies reported tumor regression and enhanced cytotoxic activity, suggesting dual antigen targeting could disrupt resilient tumor microenvironments. 👉  Why it matters:  CAR-NK therapies are gaining momentum, offering new avenues where CAR-T might face challenges, especially in solid tumors and certain hematologic malignancies. 🛑 Discontinuations ⭐  Atara’s Discontinuation of Two Allogeneic CAR-Ts   ( Ref ) Atara Biotherapeutics  discontinued all development activities for ATA3219 (an allogeneic, anti-CD19 EBV CAR-T) currently in Phase 1 for the treatment of B-NHL and ATA3431 (an allogeneic, anti-CD19/CD20 bispecific EBV CAR-T) in preclinical development for the treatment of B-cell malignancies. 👉  Why it matters:  The decision could be attributed to regulatory challenges, including the FDA's clinical hold on ATA3219, as well as manufacturing compliance issues that have presented considerable difficulties for Atara. Section 2: Cell Therapies Pipeline Landscape – An Overview As an oncology-focused business consulting firm, we closely monitor emerging modalities in the oncology space. We weekly track over 4,500 preclinical and clinical CGT programs, covering 75 critical parameters—ranging from basic details and molecular characteristics to clinical outcomes. CAR-T therapies, with over 3,700 programs (2,000+ for the treatment of Haematological Cancers), including 30 programs in the regulatory phase (refer exhibit 1a). dominate the CGT landscape. Globally, 13 unique CAR-T therapies have received approval for treating various hematological malignancies, while two more are currently under regulatory review. Notably, more than 2,000 programs are being developed for the treatment of Haematological Cancers. Moving to TCR-T therapies, a different type of engineering observed on T-cells, TCR-T therapies are steadily gaining prominence, with around 380 programs in development (refer exhibit 1b). Notably, one TCR-T therapy has been approved for the treatment of synovial sarcoma, marking a significant milestone in the field. An Overview of CAR-Ts and TCR-Ts Beyond CAR-T and TCR-T therapies, CAR-NK therapies are emerging as a promising alternative, leveraging the natural cytotoxic capabilities of NK cells for therapeutic applications. Currently, 330 CAR-NK programs are under development, with 217 still in the early stages, reflecting strong research interest in this modality. Other cell therapies, such as CAR-macrophages and CAR-NKTs, are also being explored, but their numbers remain limited. An Overview of CAR-NKs and CAR-NKTs That’s all for our first edition of CGT Watch! We will update these charts / this space every month and hope our efforts help you keep a pulse on the ever-changing competitive landscape. A Request We’d love your feedback—what did you find most interesting? If you have any questions or insights, feel free to hit reply or reach out. We look forward to exploring more breakthroughs with you in our next newsletter. Until next time,  CGT Watch Team

The first-line metastatic Melanoma market is currently dominated by immune checkpoint inhibitors—BMS' Opdivo + Yervoy, Opdualag, Opdivo, and Merck/MSD's Keytruda. Other treatment options include BRAF/MEK inhibitors (for BRAF+ve pts). Currently, Opdivo + Yervoy is considered as the gold standard with an mOS of 71.9 months; however, it is associated with a high rate of Gr 3/4 TRAEs (62.6%). BMS' Opdualag, a combination of anti-LAG-3 (relatlimab) + anti-PD-1 (nivolumab), entered the US market at the end of Q1'22. It has been positioned as a safer alternative to Opdivo + Yervoy, and a more effective option compared to anti-PD-1 monotherapies. However, it could not cross the OS benchmark set by Opdivo + Yervoy, and its efficacy in PD-L1-positive patients is not widely accepted. Nevertheless, within less than three years, Opdualag has captured 30% of the 1L Melanoma market share. With global revenue clocking close to $1B ($928 million to be precise) in 2024, Opdualag is expected to become a blockbuster in 2025. Whether Opdualag would continue minting $1B every year after 2025 is uncertain, as the first-line melanoma landscape is poised for a pivotal year, with readouts expected from   four Phase 3 trials in 2025 . The upcoming data releases may reshape the competitive landscape and set new benchmarks. To get a quick snapshot of where each regimen stands currently, we have developed a scatter plot highlighting efficacy, safety metrics, and enrollment numbers (N) from proof-of-concept and Phase 3 trials of all the key assets. To gain access to a complimentary version of this visual, please click here . Here’s a quick rundown of the trials: The first three regimens elicited promising proof-of-concept data, while the fourth is already approved as an IV formulation. We are all eager to see whether any of these can surpass the established safety and efficacy benchmarks. Of course, we will need overall survival data to really determine which (if any) can steal the crown. By the  end of the year , we also anticipate the list of key pivotal trials to grow , with promising results anticipated from key proof-of-concept trials, which include: BioAtla’s evalstotug (novel CTLA-4 agent) + anti-PD-1 reported promising results at SITC 2024, based on which the company plans initiation of a pivotal trial in 2025 Mature results for Scancell’s SCIB1/iSCIB1+ (DNA-based cancer vaccines) + nivolumab + ipilumab will inform the next steps for selection of the asset for pivotal trial initiation Results from the randomized trial of BioNTech & Roche’s autogene cevumeran (mRNA vaccine) + pembrolizumab vs pembrolizumab are anticipated Initial data for Moderna’s mRNA-4359 (IDO/PD-L1 mRNA vaccine) + pembrolizumab from the 1L melanoma cohort are anticipated at a major medical meeting Here are some interesting questions related to the 1L Melanoma space: How is the 1L melanoma landscape expected to evolve over the next five years? Which regimens have the potential to enter this space? Can Regeneron's LAG-3 inhibitor (fianlimab) + cemiplimab displace BMS's Opdualag? Are cancer vaccines finally poised to make a significant impact on the melanoma treatment paradigm? What are the emerging mechanisms of action (MoAs) shaping the future of melanoma treatment? What are the other regimens currently in pivotal trials, and when can we expect data readouts? If you have any such questions about the developments in Melanoma and are looking for insights on the impact of these developments, reach out to us at support@oncofocus.com! As an oncology-focused business consulting firm, we are known to provide deeper insights related to cancer indications. Our digital competitive intelligence services set a new benchmark and are well appreciated by industry leaders. To know more details about all our services, please select a date and time of your convenience  here .

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA. In December 2023, the FDA approved enfortumab vedotin-ejfv + pembrolizumab for first-line patients with locally advanced/metastatic (la/m) Urothelial Cancer (UC). This combination was previously granted accelerated approval in April 2023 for patients with la/m UC who are ineligible for cisplatin-containing chemotherapy. Further in March 2024, nivolumab + cisplatin + gemcitabine was approved for frontline treatment of unresectable/metastatic cisplatin-eligible UC patients. The current infographic provides a concise overview of the evolving treatment landscape of Bladder Cancer, spotlighting both established and emerging therapeutic approaches. Join us in recognizing May as Bladder Cancer Awareness Month by exploring the evolving strategies in the fight against this disease.

Esophageal cancer is the fourteenth most commonly diagnosed cancer and the eighth leading cause of cancer-related death worldwide. The burden of esophageal cancer incidence and mortality is steadily increasing worldwide due to increased prevalence of associated risk factors such as tobacco and alcohol consumption, poor diet, sedentary lifestyle and obesity. Despite advancements in targeted therapies and immunotherapies, the prognosis of Esophageal cancer remains dismal, with a 5-year survival rate of about 20%. The present infographic provides a concise overview of the current treatment landscape of Esophageal cancer, spotlighting both established and novel therapeutic approaches, and underscoring the critical need for continued research and development to improve outcomes of the same. Join us in recognizing April as Esophageal Cancer Awareness Month by exploring the evolving strategies in the fight against this disease.

CAR-T therapy has dramatically changed the course of cancer management over the past few years. However, despite this impact, one of the key challenges about the CAR-T therapies is its highly complex and long manufacturing process. With this lengthy manufacturing time and long wait-time, patients face higher chance of disease progression. To address this scenario, many novel platforms which promote rapid production of CAR-Ts are underway. Several steps utilized in conventional CAR-T production are bypassed and replaced with novel strategies to reduce time. The current slide deck comprehensively summarizes such rapid CAR-T production platforms, the therapeutic areas that are being targeted and their development phase. Please write to us at – support@oncofocus.com To get a comprehensive analysis of each of these rapid CAR-T manufacturing platforms and details of all the rapid CAR-T assets To access clinical outcomes of the CAR-T assets manufactured by the rapid CAR-T platforms To understand other research strategies under investigation to improve the efficacy of CAR-T therapies To get complete access to the landscape of CAR-Ts and other cell and gene therapies

Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for roughly 3% of all cancer diagnoses, with a notably higher occurrence in Western countries, likely linked to the increased detection of small renal masses. Despite advancements in targeted therapies and immunotherapies, the prognosis for stage IV RCC remains challenging, with a 5-year survival rate of only 17%. Furthermore, non-clear cell RCC, which constitutes about 20-25% of RCC cases, continues to present a significant unmet need in terms of treatment options. Our infographic provides a succinct overview of the current treatment landscape for RCC, spotlighting both established and novel therapeutic approaches. It underscores the critical need for continued research and development to improve outcomes for all RCC patients, particularly those with non-clear cell histologies. Join us in recognizing March as Kidney Cancer Awareness Month by exploring the evolving strategies in the fight against this disease.

PD-(L)1 axis inhibits CAR-T cell activation, proliferation, survival, and functionality. Thus, CAR-T mediated direct targeting of the PD-(L)1 immunosuppressive axis or modulation of the axis along with CAR-T therapy holds a huge promise to unleash the full potential of CAR-Ts. Multiple strategies are under investigation to target PD-(L)1 immunosuppressive axis to increase CAR-T therapy efficacy. We have grouped the strategies under the following three broad categories, Combining CAR-Ts with PD-(L)1 inhibitors to target PD-(L)1 molecules Engineering T-cells in CAR-Ts with molecular mechanisms to block PD-(L)1 axis Modifying CARs to target the PD-(L)1 axis Currently, 205+ CAR-T programs are investigating such strategies in clinical and preclinical studies. Some of these studies have shown promising efficacy and considerable safety profiles, thus providing a strong impetus for further progress along this path. In this slide deck, the Oncofocus’ Cell and Gene therapy team provided a top-level summary of all the different strategies/sub-strategies employed to target the PD-(L)1 axis with CAR-Ts or along with CAR-Ts. To get a detailed report along with the list of all the 205+ programs, active developers, current status, clinical outcomes, etc., please write to us at support@oncofocus.com. Please write to us at – support@oncofocus.com ​ To get a comprehensive analysis of each of these strategies and details of all the programs​ To access clinical outcomes of all the programs evaluating these strategies​ To understand other research strategies under investigation to improve the efficacy of CAR-Ts​ To get complete access to the landscape of 3,000+ CAR-Ts and other cell and gene therapies​